Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- HARP
- Price
- -
- Stock movement up
- +- (%)
- Company name
- Harpoon Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 492.35M
- Ent value
- 517.65M
- Price/Sales
- 13.19
- Price/Book
- 108.42
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return
- 215.21%
- 3 year return
- -50.88%
- 5 year return
- -29.44%
- 10 year return
- -
Last updated: 2024-12-17
DIVIDENDS
HARP does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 13.19 |
| Price to Book | 108.42 |
| EV to Sales | 13.86 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 21.40M |
| EPS (TTM) | -7.82 |
| FCF per share (TTM) | -17.60 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 37.34M |
| Gross profit (TTM) | 34.52M |
| Operating income (TTM) | -39.12M |
| Net income (TTM) | -30.86M |
| EPS (TTM) | -7.82 |
| EPS (1y forward) | -4.52 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 92.45% |
| Operating margin (TTM) | -104.77% |
| Profit margin (TTM) | -82.66% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 17.74M |
| Net receivables | 0.00 |
| Total current assets | 34.30M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 12.71M |
| Total assets | 47.58M |
| Accounts payable | 3.44M |
| Short/Current long term debt | 14.50M |
| Total current liabilities | 18.11M |
| Total liabilities | 43.04M |
| Shareholder's equity | 4.54M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -69.38M |
| Capital expenditures (TTM) | 119.00K |
| Free cash flow (TTM) | -69.50M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -679.70% |
| Return on Assets | -64.87% |
| Return on Invested Capital | -410.71% |
| Cash Return on Invested Capital | -924.82% |
STOCK INFORMATION
Downside potential
Loading...
Downside potential data
| HARP | S&P500 | |
| Current price drop from All-time high | -90.69% | -0.69% |
| Highest price drop | -98.67% | -56.47% |
| Date of highest drop | 12 Oct 2023 | 9 Mar 2009 |
| Avg drop from high | -59.33% | -10.99% |
| Avg time to new high | 91 days | 12 days |
| Max time to new high | 955 days | 1805 days |
COMPANY DETAILS
Marketcap
492.35M
Marketcap category
Small-cap
Description
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. It has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. The company was incorporated in 2015 and is headquartered in South San Francisco, California. As of March 11, 2024, Harpoon Therapeutics, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.
Employees
53
Website
Investor relations
-
SEC filings
CEO
Gerald McMahon
Country
USA
City
South San Francisco
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner